NKGEN Biotech

Focus: NKGEN Biotech is a public-stage biotechnology company headquartered in Santa Ana, CA, specializing in autologous and allogenic Natural Killer cell therapies for cancer, neuroinflammation, and other indications. The company is in early clinical development with a focused pipeline spanning gene and cell therapy modalities.

Gene Therapy Cell Therapy

Profile data last refreshed 7h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About NKGEN Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow NKGEN Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SNK02

Pathologically Confirmed Cancer Refractory to Conventional Therapy

PHASE_1

Clinical Trials (1)

NCT05990920Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Phase 1

Help build intelligence for NKGEN Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline with 8 distinct programs across oncology and neurology, offering exposure to mechanistically novel NK cell platforms (SNK01, SNK02, AFM24) in Phase 1–2 trials
Public-stage company with recent trial-site expansion (May 2026) and mechanism-of-action data presentations, signaling active capital deployment and clinical momentum
Emerging modality (NK cell therapy) in high-growth cell therapy segment with potential for rapid advancement if early-stage data supports efficacy

Watch Out For

Zero marketed products and no revenue generation; all programs remain in Phase 1–2, with no Phase 3 initiations or FDA catalysts on the immediate horizon
No reported hiring (0 active job openings) despite public status, suggesting either lean operations or slower scaling; limited transparency on headcount, funding, or cash runway
Early-stage clinical data (only 3 publications), and NK cell immunotherapy remains mechanistically and clinically unproven at scale compared to established CAR-T platforms

Generated by Claude from NKGEN Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SNK01

Refractory Cancer

PHASE_1

Clinical Trials (1)

NCT03941262Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Phase 1

SNK01

Alzheimer Disease

PHASE_1

Clinical Trials (1)

NCT04678453Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Phase 1